Rocket Lab's $2.36 Billion Backlog Can't Quiet the Doubters
Published on 08/22/2026 at 20:03 | Redaktion boerse-global.de
The numbers keep getting bigger, and so does the skepticism. Rocket Lab closed the week at €62.40, barely moving on Friday, yet the equity has shed a tenth of its value over the past seven sessions. That divergence — a torrent of contract announcements colliding with a stubbornly weak share price — captures the central tension surrounding the space company right now.
For the bulls, the case has rarely looked stronger. The order book stands at $2.36 billion, up 137 percent year over year, while second-quarter revenue hit a record $234 million, a 62 percent jump. The company has bagged a $266 million Space Force contract for roughly a dozen suborbital launches, a $190 million Pentagon award for hypersonic testing, and a slice of the $981 million NITE-STAR program. Add in the planned $8 billion acquisition of Iridium Communications, slated to close in mid-2027, plus NASA study contracts for a Mars Telecommunications Orbiter and participation in Mars Sample Return missions in the 2030s, and the growth narrative appears almost overwhelming.
A Political Tailwind That Lifts Everyone
The macro environment has shifted decisively in the industry's favor. The White House signed a new national space memorandum on Friday aiming to enable more than 1,000 US launches per year by 2030 — the first fundamental policy overhaul since 2013. Meanwhile, the Space Force has expanded its Phase 3 Lane 1 contracts by $11.4 billion, bringing the total to $17 billion. Government demand for commercial launch capacity is being scaled up aggressively, and Rocket Lab sits squarely within that pipeline.
Yet there is a complication the market seems unwilling to ignore: this tailwind benefits the entire sector, not just Rocket Lab. SpaceX accounted for 85 percent of all US orbital launches in 2025 and is now testing all six Raptor-3 engines on its Starship upper stage ahead of a first orbital flight. Chinese rivals like Landspace are advancing reusable boosters of their own. The competitive field is professionalizing at a rapid clip, and political support alone does not differentiate one player from another.
The Neutron Question Looms Larger
The real test remains the Neutron rocket. The vehicle's first launch has been a moving target — originally slated for the fourth quarter, market observers now suggest it could slip into 2027. For a company whose valuation hinges on future growth, that timeline matters enormously. Until Neutron actually flies, the growth story remains theoretical, no matter how many contracts accumulate in the backlog.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The financials underscore the strain. Free cash flow in the second quarter came in at negative $110.1 million, and the first-half net loss reached $94 million. The Iridium deal, strategically compelling as it may be, ties up capital for a long stretch — nearly two years before closing — during which much can change. CEO Peter Beck sought to reassure investors on Friday that the acquisition is not a frontal challenge to Starlink, describing the L-band spectrum strategy as something "that has never existed before." It is a differentiation pitch, not a head-on collision with Elon Musk's satellite empire.
A Valuation That Leaves No Room for Error
The analyst community remains split. Seeking Alpha analysts upgraded the stock to Buy on Friday, citing the Mars ambitions and expanding backlog as offsets to the delayed Neutron timeline, with a support zone around $57. BTIG, by contrast, maintains a Hold rating. The consensus sits somewhere between "Strong Buy" and caution.
The bear case is straightforward: at a market value of roughly €44.32 billion, the stock trades at about 59 times trailing twelve-month revenue — a multiple that affords little tolerance for further setbacks. Bulls counter with a price-to-book ratio of 12.4, below the roughly 20 typical of comparable growth names, and point to DCF models suggesting the equity is undervalued by as much as 38 percent.
Institutional ownership has climbed to nearly 72 percent, with BlackRock and Vanguard among the larger holders and several smaller funds and sovereign wealth vehicles adding positions during the second quarter. Yet insiders sold roughly $351 million worth of shares over the past 90 days, and short interest stands at 8.65 percent of the float. Hedge fund Marshall Wace increased its position by over 1,200 percent, a striking bet against the prevailing narrative.
A Stock That Moves to Its Own Rhythm
The share price sits about 53 percent below its 52-week high of €133.80, and roughly 13 percent under the 50-day moving average of €71.40. The relative strength index of 42 suggests not oversold conditions but something closer to directionlessness. Over the past month the stock is still up 1.8 percent, and on a yearly basis it has gained 74 percent — the long-term trend remains intact even as short-term momentum has broken.
The 78 percent volatility reading, whether measured on a 30-day or annualized basis, tells its own story. This is a stock that moves hard in both directions, and the news flow has done little to settle it down. Wednesday brought the 93rd Electron mission, carrying a synthetic aperture radar satellite for Japanese customer QPS — routine execution that barely registered against the broader noise.
What the market appears to be weighing is not whether Rocket Lab has a promising future, but whether the current price already assumes that future has arrived. The backlog, the Mars contracts, the Iridium deal, the policy tailwinds — all of it points to a company with genuine strategic momentum. But the negative cash flow, the unproven Neutron, and a valuation that prices in considerable success leave little margin for disappointment. Until that first Neutron launch clears the pad, the stock may remain more a vehicle for speculation than conviction.
Ad
Rocket Lab Stock: New Analysis - 22 August
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
